تحميل...
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease. As more potent FLT3...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
American Society of Hematology
2014
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3879910/ https://ncbi.nlm.nih.gov/pubmed/24227820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-529313 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|